James Robert Platt

James Robert Platt

Auto-generated profile, based on publicly available information

James Robert Platt

University of Leeds Division of Oncology, Leeds Institute of Medical Research at St James's, School of Medicine Leeds, LS2 9JT

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TSThomas Starkey
Thomas Starkey
MIMaria C. Ionescu
Maria C. Ionescu
MTMichael Tilby
Michael Tilby
MLMartin Little
Martin Little
EBEmma Burke
Emma Burke
LLLennard Y. W. Lee
Lennard Y. W. Lee
Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.

5 September 2024 in ESMO Open
Verified
Journal Article
Open access
JPJ.R. Platt
J.R. Platt
JAJ. Allotey
J. Allotey
EAE. Alouani
E. Alouani
JGJ. Glasbey
J. Glasbey
RIR. Intini
R. Intini
JSJ.F. Seligmann
J.F. Seligmann
Immunotherapy is used routinely for treating deficient mismatch repair (dMMR) colon cancer (CC). This case series highlights an emerging safety issue, where patients develop bowel obstruction associated with immunotherapy response. Patients with dMMR CC who developed bowel obstruction while responding to immunotherapy were retrospectively identified. Data on patient, disease, treatment, and response-specific factors were explored for potential risk factors. Overall treatment numbers were used to estimate incidence. Nine patients from eight European centres were included. Common features were hepatic flexure location (5/9), T4 radiological staging (6/9), annular shape (8/9), radiological stricturing (5/9), and endoscopic obstruction (6/9). All received pembrolizumab and obstructed between 45 and 652 days after starting treatment. Seven patients underwent surgical resection; one was managed with a defunctioning stoma; and one was managed conservatively. One patient died from obstruction. Radiological response was seen in eight patients, including two complete responses. Pathological response was seen in all seven who underwent resection, including four complete responses. The overall incidence of immunotherapy response-related obstruction in these centres was 1.51%. Bowel obstruction associated with immunotherapy response may represent a rare treatment-related complication in dMMR CC. Clinicians must recognise this safety signal and share experience to maintain patient safety.

26 July 2023 in British Journal of Radiology
Verified
Journal Article
Open access
JPJames R Platt
James R Platt
JAJennifer Ansett
Jennifer Ansett
JSJenny F Seligmann
Jenny F Seligmann
NWNicholas P West
Nicholas P West
DTDamian J M Tolan
Damian J M Tolan
Objective: Mismatch repair (MMR) deficient (dMMR) colon cancer (CC) is distinct from MMR proficient (pMMR) CC, yet the impact of MMR status on radiological staging is unclear. The purpose of this study was to investigate how MMR status impacts CC CT staging. Methods: We retrospectively compared CT staging accuracy between dMMR and pMMR CC patients undergoing curative resection. Accuracy was assessed as individual tumour (T)/nodal (N) stages and as dichotomous “statuses” (T1/2 vs T3/4; N0 vs N1/2). Patient characteristics were analysed for factors to support staging. Results: There was no significant difference in overall staging accuracy between the dMMR (44 patients) and pMMR (57 patients) groups. dMMR tumours with incorrect N stage/“status” were more likely to be overstaged than pMMR tumours (90% vs 59%; p = 0.023 for “N status”). Platelet count, CRP and neutrophil count (AUC 0.76 (p = 0.0078), 0.75 (p = 0.034) and 0.70 (p = 0.044), respectively) were associated with “N status” in dMMR tumours. Conclusion: Whilst overall staging accuracy was similar between groups, incorrectly N staged dMMR tumours were more likely to be overstaged than pMMR tumours, risking inappropriate surgical or neoadjuvant treatment. We describe novel relationships between several inflammatory markers and pathological “N status” in dMMR CC, which if integrated into routine practice may improve CT staging accuracy. Advances in knowledge: Compared to pMMR CC, dMMR CC is at significant risk of N overstaging. Platelet count, CRP and neutrophil count are higher in dMMR CC patients with nodal metastases than those without, and their role in refining clinical staging requires further investigation.

15 February 2023 in Colorectal Disease
Verified
Journal Article
Open access
JPJames R. Platt
James R. Platt
CWChristopher J. M. Williams
Christopher J. M. Williams
ZCZoe Craig
Zoe Craig
DCDavid A. Cairns
David A. Cairns
JGJames C. Glasbey
James C. Glasbey
JSJenny Seligmann
Jenny Seligmann
Aim: FOxTROT1 established a new standard of care for managing locally advanced colon cancer (CC) with neoadjuvant chemotherapy (NAC). Six weeks of neoadjuvant oxaliplatin and fluoropyrimidine (OxFp) chemotherapy was associated with greater 2‐year disease‐free survival (DFS) when compared with proceeding straight to surgery (STS). There is now a need to refine the use of NAC and identify those most likely to benefit. FOxTROT2 will aim to investigate NAC in older adults and those with frailty. FOxTROT3 will aim to assess whether intensified triplet NAC provides additional benefits over OxFp.Method: FOxTROT2 and FOxTROT3 are international, open‐label, phase III randomized controlled trials. Eligible patients will be identified by the multidisciplinary team. Patient age, frailty and comorbidities will be considered to guide trial entry. Participants will be randomized 2:1 to the intervention or control arm: 6 weeks of dose‐adapted neoadjuvant OxFp versus STS in FOxTROT2 and 6 weeks of neoadjuvant modified oxaliplatin, 5‐fluorouracil and irinotecan versus OxFp in FOxTROT3. The primary endpoint in FOxTROT2 is 3‐year DFS. In FOxTROT3, tumour regression grade and 3‐year DFS are co‐primary endpoints.Discussion: FOxTROT2 and FOxTROT3 will establish the FOxTROT platform, a key part of our long‐term strategy to develop neoadjuvant treatments for CC. FOxTROT2 will investigate NAC in a population under‐represented in FOxTROT1 and wider research. FOxTROT3 will assess whether it is possible to induce greater early tumour responses and whether this translates to superior long‐term outcomes. Looking ahead, the FOxTROT platform will facilitate further trial comparisons and extensive translational research to optimize the use of NAC in CC.

13 February 2025 in European Journal of Radiology
Verified
Journal Article
Open access
JPJames R. Platt
James R. Platt
SPStephanie Pennycook
Stephanie Pennycook
CMChand E. Muthoo
Chand E. Muthoo
AWAlice C. Pathology Nick Westwood
Alice C. Pathology Nick Westwood
RFRussell Frood
Russell Frood
DTDamian J.M. Tolan
Damian J.M. Tolan
In the era of precision oncology, systemic therapies for colon cancer are becoming increasingly biomarker-led, with implications for patients in the neoadjuvant, adjuvant and metastatic settings. As the landscape for colon cancer treatment evolves and becomes more complex, it is important that all members of the multidisciplinary team keep abreast of developments to ensure the most effective care is delivered to patients. As core members of the colorectal multidisciplinary team, Radiologists play a central role throughout the patient journey. This review serves as an educational summary of current and emerging treatment pathways in colon cancer, standards for biomarker testing, mechanisms of action for key drugs, important treatment-related complications, relevant tumour biology that underpins patterns of disease and treatment response, and the specific implications systemic therapies have for cancer imaging and Radiologists. We also highlight the increasing role for radiology in patient stratification and the importance of imaging biomarkers. It is crucial that Radiologists understand the current landscape of colon cancer treatment and emerging strategies on the horizon in clinical trials. Only through engagement across the wider multidisciplinary team will we deliver true personalised medicine for patients with colon cancer.

23 August 2025 in British Journal of Radiology
Verified
Journal Article
Open access
JPJames R Platt
James R Platt
FEFaye Elliott
Faye Elliott
KHKelly Handley
Kelly Handley
LMLaura Magill
Laura Magill
PQPhilip Quirke
Philip Quirke
DTDamian J M Tolan
Damian J M Tolan
Objectives: In the Fluorouracil, Oxaliplatin and Targeted Receptor pre-Operative Therapy (FOxTROT) trial, neoadjuvant chemotherapy (NAC) significantly reduced recurrence risk, compared to upfront surgery, in locally advanced colon cancer. This analysis evaluates the correlation between radiological and pathological staging within the trial to support the adoption of CT-based patient selection. Methods: In this preplanned analysis of prospectively collected data, local radiological and pathological staging were compared in upfront surgery participants. T stage, N stage, and extramural venous invasion (EMVI) status were evaluated using overall agreement, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Subgroup analyses explored the impact of mismatch repair status and tumour side. Results: A total of 354 participants were included. T stage agreement was 63.0%; T3 and T4 tumours were correctly identified in 78.9% and 41.1% of participants, respectively. The PPV for T3-4 status was 94.5%. N stage agreement was 39.8%; for N status (positive vs. negative), overall agreement, sensitivity, specificity, PPV, and NPV were 54.1%, 81.1%, 26.0%, 53.2%, and 57.1%, respectively. For EMVI, these values were 54.9%, 71.0%, 41.2%, 50.7%, and 62.5%, respectively. Accuracy metrics did not differ significantly by tumour side or mismatch repair status. Conclusions: CT effectively predicted T3-4 status with minimal overstaging, but performed poorly for individual T stage, N stage, and EMVI. We propose radiological T3-4 status should be adopted as the primary biomarker for neoadjuvant patient selection, with molecular biomarkers to guide treatment choice. Advances in knowledge: In this multicentre trial, local radiologists accurately identified T3-4 status to select participants for NAC, indicating utility for future neoadjuvant trials and clinical practice.